Journal of Clinical Oncology

Vol. 43, Issue 21 Issue 21 2025
13
Articles

Articles in this Issue

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab

Ross A. Soo, Victor Ho-fun Lee, Daniel Shao-Weng Tan et al. Jul 20, 2025 pp. 2387-2397 10.1200/jco-25-00763

PURPOSE To evaluate the safety and efficacy of zipalertinib, an irreversible epidermal growth factor receptor (EGFR) inhibitor, in pretreated patients with non–small cell lu...

Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma

Dan P. Zandberg, Jacob B. Allred, Ari J. Rosenberg et al. Jul 20, 2025 pp. 2398-2408 10.1200/jco-25-00759

PURPOSE Continued improvement in outcomes is needed for advanced cutaneous squamous cell carcinoma (cSCC). Methods Alliance A09...

Tumor-Treating Fields Open the Door to Progress for Patients With Locally Advanced Pancreatic Cancer

Michael J. Pishvaian Jul 20, 2025 pp. 2339-2342 10.1200/jco-25-01040

Reply to: Comment on The Study of NRG258: Limitations and Future Directions

Daniela Matei Jul 20, 2025 pp. 2450-2451 10.1200/jco-25-00473

Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma

Matheus Sewastjanow-Silva, Lianchun Xiao, Ahmed Abdelhakeem et al. Jul 20, 2025 pp. 2361-2371 10.1200/jco-24-01678

PURPOSE To compare overall survival (OS) in patients with baseline metastatic gastric adenocarcinoma (GA) with and without ovarian metastasis (OM). Furthermore, within the group that had o...

Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma

Jae H. Park, M. Lia Palomba, Karlo Perica et al. Jul 20, 2025 pp. 2418-2428 10.1200/jco-24-02424

PURPOSE We designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB...

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ <i>TP53</i> Mutation: SEQUOIA Arm D Results

Mazyar Shadman, Talha Munir, Shuo Ma et al. Jul 20, 2025 pp. 2409-2417 10.1200/jco-25-00758

PURPOSE Several chronic lymphocytic leukemia (CLL) studies have demonstrated promising efficacy with the combination of BCL2 and Bruton tyrosine kinase inhibitors; however,...

Comment on The Study of NRG258: Limitations and Future Directions

Yue-Can Zeng, Ming Xue, Jun-Nv Xu et al. Jul 20, 2025 pp. 2449-2450 10.1200/jco-24-02826

Mindfulness and Tai Chi for Cancer Health (MATCH) Study: Primary Outcomes of a Preference-Based Multisite Randomized Comparative Effectiveness Trial

Linda E. Carlson, Jennifer M. Jones, Devesh Oberoi et al. Jul 20, 2025 pp. 2372-2386 10.1200/jco-24-02540

PURPOSE Many cancer survivors have high levels of distress and psychosocial symptoms. Two mind-body interventions for treating these problems are Mindfulness-Based Cancer Recovery (MBCR) a...

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

Hani M. Babiker, Sreenivasa R. Chandana, Jin Gang et al. Jul 20, 2025 pp. 2350-2360 10.1200/jco-25-00746

PURPOSE Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. Feasibility of TTFields therapy with gemcitabine/nab-paclitaxel was previousl...

Nephrotoxicity Surveillance for Childhood and Young Adult Survivors of Cancer: Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group

Esmee C.M. Kooijmans, Renée L. Mulder, Stephen D. Marks et al. Jul 20, 2025 pp. 2433-2448 10.1200/jco-24-02534

PURPOSE Childhood, adolescent, and young adult (CAYA) survivors of cancer are at risk of nephrotoxicity. Surveillance guidelines are important for timely diagnosis and treatment of these s...

Calibrating Chimeric Antigen Receptor (CAR) Signaling to Improve CAR T-Cell Therapies

Cooper J. Sailer, Chelsea E. Peterson, Marco L. Davila Jul 20, 2025 pp. 2429-2432 10.1200/jco-24-02792

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

Enriqueta Felip, Nasser Altorki, Caicun Zhou et al. Jul 20, 2025 pp. 2343-2349 10.1200/jco-24-01681

IMpower010 (ClinicalTrials.gov identifier: NCT02486718 ) previously showed that atezolizumab improved disease-free survival (DFS) versus best supportive care (B...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page